id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-N-5344-0001,FDA,FDA-2023-N-5344,"Pharmacyclics LLC.; Withdrawal of Approval of Indications for Mantle Cell Lymphoma and Marginal Zone
Lymphoma for IMBRUVICA (ibrutinib) Capsules and Tablets",Notice,Withdrawal,2023-12-18T05:00:00Z,2023,12,2023-12-18T05:00:00Z,,2023-12-18T14:30:13Z,2023-27662,0,0,09000064863439f9